CHO Cell Culture Media Market Size & Share, by Product Type (Commercial, Customized Media); Media Type (Serum-based Media, Serum-Free Media, Chemically Defined Media, Protein-Free / Hybrid Media); Formulation Form (Liquid Media, Powder / Lyophilized Media, Semi-Solid Media); End use; Media Application - Global Supply & Demand Analysis, Growth Forecasts, and Statistical Report 2026-2036

CHO Cell Culture Media Market - Regional Analysis

North America Market Insights

The North America CHO cell culture media market is expected to hold a revenue share of 39.8% by the end of 2036, owing to the presence of a vast number of biopharmaceutical companies within the region. This indicates a rising use of the media in the production of CHO cells, especially when the regulators are encouraging the use of alternatives to animal derivatives in biopharmaceutical applications. The initiation of relevant research and development is also expected to boost the advancement of the CHO cell culture media. For instance, in January 2022, Cytiva partnered with Nucleus Biologics to develop a solution for custom media formulation and fulfillment for the industry of cell and gene therapy. The plan of the companies included the use of an AI platform in the optimization of cell culture formulation.

The CHO cell culture media market in the U.S. is set to witness a CAGR of 14.7% throughout the forecast timeline, due to the growing demand for biologics, including monoclonal antibodies, driven by a surge in biopharmaceutical production. The use of the CHO cell culture media is also likely to be boosted, owing to the rising investment in the development of regenerative medicine and gene therapy. Updated in November 2023, outcomes from a simulation study conducted by the National Center for Biotechnology Information show that year-on-year spending on gene therapies is expected to reach around USD 20.4 billion. The use of CHO cell culture media is crucial in the production of therapeutic proteins required to enable cell therapies.

The Canada is poised to emerge as an expanding CHO cell culture media market between 2026 and 2036, owing to public-private partnerships in stem cell research and the development of regenerative medicine. For instance, in June 2025, the Stem Cell Network (SCN) raised funding of USD 13.5 million to undertake 36 new research projects and clinical trials on regenerative medicine. A total of 63 partner organizations supported the research initiative with an investment of USD 19.5 million, which led to a collective spending of USD 33 million to fuel the regenerative medicine ecosystem of the country. Stringent regulations for biologics and cellular therapies are also fostering innovation in CHO cell culture media to make biopharmaceutical organizations comply with the set standards.

Europe Market Insights

The Europe is anticipated to account for a revenue share of 30.8% in the global CHO cell culture media market during the forecast timeline, as a consequence of the growing prevalence of rare and chronic diseases, including autoimmune disorders, and cancer. In March 2025, the European Federation of Pharmaceutical Industries and Associations reported that the count of new cancer cases increased by around 60% in Europe since 1995, causing 23% of adult deaths, and is poised to be the leading cause of deaths by 2035. As a result, the demand for CHO cell culture media is likely to increase rapidly for the production of therapeutic proteins used in cancer treatment. The consumption of the media is also estimated to increase with the rapid expansion of the biosimilar market across the region.

The CHO cell culture media market in the UK can experience a CAGR of 16.1% by 2026, owing to the plan of government to make the country the global leader in life sciences. In July 2025, the government launched the Life Sciences Sector Plan, a part of the Industrial Strategy. The aim behind the initiative is to bolster the science and innovation of the country so that long-term economic growth and a strengthened, prevention-focused national health service can be enabled. This is likely to lead to a growing demand for CHO cell culture media in bioproduction. The adoption of the media is also likely to be accelerated with increasing investment in the biotechnology industry in the upcoming years. For instance, according to the disclosure by the BioIndustry Association in July 2025, the life science sector of the country secured a venture capital investment of around USD 1.6 billion during the first half of 2025.

The Germany CHO cell culture media market is estimated to go through a rapid expansion throughout the forecast period, on account of the rapid involvement of key biopharmaceutical products and research institutions in the development of the new vaccines and therapeutics. Growing investment in pharmaceutical research and development is also expected to fuel the consumption of the CHO cell culture media. As disclosed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) in November 2024, Germany spent approximately USD 11.4 billion in pharmaceutical research and development in 2023.

Asia Pacific Market Insights

The CHO cell culture media market in the Asia Pacific is poised to witness a 15.4% CAGR from 2026 to 2036, owing to the emergence of the region as the hub for contract research and manufacturing of the biopharmaceutical and biotechnology products. Governments of different countries are also attracting foreign direct investments for the biopharmaceutical production. As a result, the consumption of the CHO cell culture media is estimated to surge in the forthcoming business period. Technological advancements in the region are driving improvements in media formulation. For example, in November 2023, Ajinomoto CELLiST Korea launched the innovative CELLiST F7, featuring cysteine stabilization technology. This enables the delivery of higher cysteine concentrations to cells, enhancing culture performance and overall productivity.

The CHO cell culture media industry in China is projected to witness robust growth during the forecast timeline, with adequate government support in the advancement of life sciences. According to the update by the Information Technology and Innovation Foundation in September 2024, the government of China is providing remarkable direct and indirect subsidies to chemical firms as part of the Made in China 2025 strategy. This development enhances accessibility to CHO cell culture media for companies, while the growing foreign direct investment in cell therapy in China is expected to further drive its adoption.

The CHO cell culture media market is poised to grow exponentially in India over the forecast horizon, as a consequence of the growing demand for biopharmaceuticals. The demand is driven by an aging population and the increasing prevalence of chronic diseases. As revealed by the International Society for Pharmaceutical Engineering in April 2025, India is currently the largest supplier of vaccines, fulfilling 62% of the global demand by exporting two-thirds of the vaccines produced. The growing adoption of cell-based therapies is also expected to boost the consumption of the CHO cell culture media across the country in the years ahead.